Meda acquires Treo

Meda acquires Treo

 

Meda has agreed to acquire three well-established Nordic OTC drugs from
McNeil AB/Cilag GmbH International, members of the Johnson & Johnson
Consumer Companies. Treo is the main drug. Annual sales for all three
products total approximately 210 MSEK.

Meda will acquire all rights to the drugs. The purchase price is 82 MEUR
and the transaction is expected to be finalized within a couple of
weeks.

"Meda's position within OTC drugs in the Nordic region has strengthened
significantly in the last year. Meda becomes the largest company within
prescription free pharmaceuticals in Sweden through the acquisition of
Treo”, said Anders Lönner, CEO of Meda AB.

For further inquiries, please contact:

Anders Larnholt, Vice President Corporate Development & IR ph: 46
709-458 878